Allergan taps Celgene vet Hugin for M&A guidance, but proxy brawlers aren't impressed

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech executive for guidance. But if the company thought those moves would be enough to placate angry activists, it was wrong.